IP Library › Granted Patent US 12,410,232
Granted Patent B2
US 12,410,232 · App. 17/462,925 · Granted Sep 9, 2025

Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor

Inventors: Nicola Mason (Philadelphia, PA); Daniel J. Powell, Jr. (Bala Cynwyd, PA); Mohammed Kazim Panjwani (Philadelphia, PA); Jenessa Smith (San Diego, CA); Laurence J.N. Cooper (Park City, UT); Colleen M. O'Connor (Houston, TX)
Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA; Board of Regents, The University of Texas System
C07K14/70517A61K40/11A61K40/31A61K40/4221A61P35/00C07K14/7051C07K14/70521C07K14/70578C07K16/2887C12N5/0638A61K2039/552C07K2317/622C07K2319/03
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,410,232
App. No.
17/462,925
Granted
Sep 9, 2025
Kind
B2
Abstract

The present invention relates to compositions and methods for the treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor. One aspect includes a modified canine T cells and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with enhanced immunity in canine.

Claims (8)

1. A method of treating a CD20+ cancer in a canine, the method comprising administering to the canine a modified cell that expresses a chimeric antigen receptor comprising a canine CD20 antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the canine CD20 antigen binding domain comprises an anti-CD20 single-chain variable fragment (scFv) comprising SEQ ID NO: 2.

2. The method of claim 1 , wherein the modified cell is selected from the group consisting of a T cell, a natural killer (NK) cell, a cytotoxic T lymphocyte (CTL), and a regulatory T cell.

3. The method of claim 1 , wherein the modified cell is autologous to the canine.

4. The method of claim 1 , further comprising administering an antitumor vaccine to the canine.

5. The method of claim 4 , wherein the modified-canine-T cell and the antitumor vaccine are co-administered to the canine.

6. The method of claim 1 , wherein the cancer is selected from the group consisting of lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, lymph nodes cancer, bone marrow cancer, liver cancer, spleen cancer, ovarian cancer, renal cell carcinoma, bladder cancer, kidney cancer, testicular cancer, prostate cancer, breast cancer, colon cancer, pancreatic cancer, lung cancer, stomach cancer, eye cancer, skin cancer and any combination thereof.

7. The method of claim 6 , wherein the cancer is Hodgkin's lymphoma or non-Hodgkin's lymphoma.

8. The method of claim 1 , wherein the costimulatory signaling region comprises an intracellular domain of a costimulatory molecule selected from the group consisting of CD8, CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, and any combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2025
From: COOPER, LAURENCE J.N.; O'CONNOR, COLLEEN M.
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 071716/0593 →
Continuity (3)
Continuation 15743033
Provisional Application 62191048 · Jul 10, 2015
Related Publication 20220168351A1 · Jun 2, 2022
References Cited (21)
US 7261890B2 · Krah et al. · 2007 [cited by applicant]
US 20110091483A1 · Beall et al. · 2011 [cited by applicant]
US 20130287748A1 · June et al. · 2013 [cited by applicant]
US 20140072581A1 · Dixit · 2014 [cited by examiner]
US 20140322212A1 · Brogdon et al. · 2014 [cited by applicant]
US 20140370045A1 · June et al. · 2014 [cited by applicant]
US 20170183407A1 · Cooper et al. · 2017 [cited by applicant]
WO 03060080A2 · 2003 [cited by applicant]
Shan et al. Characterization of scFv-Ig Constructs Generated from the Anti-CD20 mAb 1F5 Using Linker Peptides of Varying Lengths (J. Immuno., 1999, 162:6589-6595) (Year: 1999). [cited by examiner]
International Search Report dated Dec. 1, 2016 in International Application No. PCT/US16/41557. [cited by applicant]
Mata , et al., “Towards immunotherapy with redirected T cells in a large animal model: Ex vivo activation, expansion, and genetic medication of canine T cells”, J. Immunother, 37(8), Oct. 2014, 407-415. [cited by applicant]
Sasai , et al., “Monoclonal Antibodies for the Diagnosis of Canine Mastocytoma”, Hybridoma, vol. 26(3), Jun. 2007, Abstract only. [cited by applicant]
Smith , et al., “Feasibility and safety of cCD20 RNA CAR-bearing T cell therapy for the treatment of canine B cell malignancies”, J. Immunotherapy of Cancer, 3(Suppl.2), Nov. 2015, 123. [cited by applicant]
Aguiar , et al., “Production of Monoclonal Antibodies Against Canine Leukocytes”, Hybridoma and Hybridomics 23 (2), 2004, 127-132. [cited by applicant]
O'Connor et al., (2013). Chimeric antigen receptor T-cell therapy for companion canines with spontaneous B-cell non-Hodgkin lymphoma. Mol Ther 21: S249. (Year: 2013). [cited by applicant]
Jubala et al. CD20 Expression in Normal Canine B Cells and in Canine non-Hodgkin Lymphoma. Vet Pathol 42:468-476 (2005) ( Year: 2005). [cited by applicant]
Rudikoff et al., Single amino acid substitution altering antigen-binding specificity. Proc. Natl Acad. Sci. USA vol. 79, pp. 1979-1983, Mar. 1982 (Year: 1982). [cited by applicant]
Winkler et al. Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody. Journal of Immunology, 2000, 165: 4505-4514. (Year: 2000). [cited by applicant]
Dechant et al., Direct submission, Oct. 9, 2001, anti-human CD20 antibody 1 F5 gamma heavy chain variable region [Mus musculus] GenBank: AAL27650.1 (Year: 2001). [cited by applicant]
Dechant et al., Direct submission, Oct. 9, 2001, anti-human CD20 antibody 1 F5 kappa light chain variable region [Mus musculus] GenBank: AAL27649.1 (Year: 2001). [cited by applicant]
Press et al., Monoclonal Antibody 1 F5 (Anti-CD20) Serotherapy of Human B Cell Lymphomas. Blood, vol. 69, No. 2 Feb. 1987: pp. 584-591 (Year: 1987). [cited by applicant]